WO2004065413A1 - 新規k01−b0171物質およびその製造法 - Google Patents
新規k01−b0171物質およびその製造法 Download PDFInfo
- Publication number
- WO2004065413A1 WO2004065413A1 PCT/JP2003/000349 JP0300349W WO2004065413A1 WO 2004065413 A1 WO2004065413 A1 WO 2004065413A1 JP 0300349 W JP0300349 W JP 0300349W WO 2004065413 A1 WO2004065413 A1 WO 2004065413A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substance
- producing
- culture
- medium
- rhodococcus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a novel ⁇ 01- ⁇ 0171 substance having antituberculous activity and a method for producing the same, wherein the ⁇ 01- ⁇ 0171 substance is derived from the ⁇ 01- ⁇ 0171 one substance and / or the ⁇ 01-BO171-C substance. It is related to a substance useful for prevention and treatment as an antituberculosis drug. Background art
- the present invention extends to a novel K0 1 -B 0 171 substance that has found an effective antituberculosis drug against M. tuberculosis that can satisfy such expectations, and a method for producing the same.
- the present invention also provides the following formula [II]
- the present invention further includes in particular the following formula [I]
- a microorganism belonging to the genus Orococcus and having the ability to produce ⁇ 0 1— ⁇ 0 1 7 1 — ⁇ substance is cultured in a medium, and ⁇ 0 1 — ⁇ 0 1 7 1— ⁇ 0 1- ⁇ 0 1 7 1 1. Collect ⁇ substances from the culture. ⁇ 0 1 ⁇ ⁇ 0 1 7 1 1. Provide a method for producing ⁇ substances.
- a microorganism belonging to the genus Orococcus and having the ability to produce ⁇ 0 1— ⁇ 0 1 7 1—C substance is cultured in a medium, and ⁇ 0 1 — ⁇ 0 1 7 1— Accumulation of C substance and collection of C substance from the culture ⁇ 0 1- ⁇ 0 1 7 1
- the present invention further includes cultivating a microorganism having the ability to produce ⁇ 0 1— ⁇ 0 1 7 1— ⁇ substance and ⁇ or ⁇ 0 1- ⁇ 0 1 7 1 ⁇ 0 1- ⁇ 0 1 7 1— Accumulate ⁇ substances and 1 0 1— ⁇ 0 1 7 1— Accumulate C substances from the culture ⁇ 0 1- ⁇ 0 1 7 1 —
- a method for producing a composition comprising a ⁇ substance and / or ⁇ 0 1 ⁇ 1 0 1 7 1—C substance.
- the present invention further relates to Rhodococcus sp. ⁇ 0 1 — ⁇ 0 1 7 1 (R) 0 1 — ⁇ 0 1 7 1 — A microorganism having the ability to produce a ⁇ substance. hodococcuss. K 0 1 -B 0 1 7 K FERM BP— 8 2 6 7) K 0 1 -B 0 1 7 1—The production method of the 1-B substance is provided.
- the present invention further relates to Rhodococcus sp. K 0 1 -B 0 1 7 1 (R hodococcuss ⁇ . K 0 1), a microorganism belonging to the genus Orococcus genus and capable of producing the substance K0 1— B 0 1 7 1—C. -B 0 1 7 K FERM BP— 8 2 6 7) K 0 1 -B 0 1 7 1
- the present invention further includes a microorganism belonging to the genus Orococcus, having the ability to sacrifice K 0 1—B 0 1 7 1—B substance and N or K 0 1 -B 0 1 7 1 C substance.
- a method for producing a composition comprising a 1-C substance is provided.
- the present invention further provides a microorganism which is Rhodococcus sp. K 0 1—B 0 1 71 (Rh 0 d 0 coc c sus sp. K 0 1 -B 0 1 7 FERM BP—826 7).
- the present invention further provides K 0 1 -B 0 1 7 1 -B substance and K0 1 -B 0 1 7 1 1 C substance, or K 0 1 -B 0 1 7 1- B for use as an antituberculosis drug
- a composition comprising a substance and a K0 1 -B 0 1 7 1-C substance is provided.
- K 0 1—B 0 1 7 1—B substance and the K 0 1 —B 0 1 71—C substance of the present invention represented by the formulas [I] and [II], or a composition comprising these substances
- Microorganisms having the ability to act (hereinafter referred to as “K 0 1—BO 1 71 1 producing bacteria”) belong to the genus Rhodococcus.
- the present inventors newly isolated Rhodococcus sp. (Rh 0 d 0 c 0 ccuss p.) K 0 1 -B 0 1 7 1 is an example of the strain most effectively used in the present invention.
- the mycological properties of the Rh odococcuss p. K 0 1 - ⁇ 0 1 71 strain of the present invention are as follows. (I) Morphological properties
- This strain is composed of sucrose 'nitrate agar, glucose asparagine agar, glycerol asparagine agar, tyrosine agar, oatmeal agar, yeast malt extract agar, nutrient agar, glucose nitrate agar.
- Medium, Glycerol ⁇ Grows well on calcium malate calcium agar and glucose peptone agar, moderately grows on starch, mineral salt agar and peptone iron agar, Mycelia do not settle. Under observation under a microscope, the cells change from gonococci to cocci, with a size of about 1.1 to 1.4 X 0.7 to 0.8 ⁇ m.
- Soluble pigment not produced Glycerol Asparagine Agar (I SP)
- Soluble pigments do not grow otomeal agar (ISP)
- Soluble pigment Slightly produced, yellow glucose nitrate agar
- Soluble pigment-producing source Peptone agar
- L-rhamnose my 0—inositol, schucrose Not used: L-arabinose, rahuinose, melibiose, D-xylose
- the cell wall diaminopimelic acid is meso-type, and the total microbial sugar contains galactose and arabinose.
- Cell wall muramic acid is a glycolyl type.
- the main menaquinone is MK-8 (H 2 ). Contains mycolic acid.
- Diaminopimelate in the cell wall is meso-type, and all microbial sugars contain galactose and arabinose.
- Cell wall muramic acid is glycolyl, and the main menaquinone is MK-8 (H 2 ).
- the cells change from short koji molds to pseudococcal fungi, and the size is about 1.1 to 1.4 X 0.7 to 0.8 m.
- the colony is orange to brown in color and does not produce melanin, but produces slightly yellow soluble pigment on peptone 'yeast' iron agar.
- this strain was identified as one species belonging to the genus M. dococcus. This strain is Rho do coc cu s sp. K01—B 0 711, based on the Budapest Treaty on the International Approval of Deposit of Microorganisms in Patent Procedures.
- K0 1 -B 0 1 71 substance-producing bacterium used in the present invention include the above-mentioned oral dococcus sp. (Rh 0 d 0 c 0 ccuss p.) K 01- B 0 1 71 strain.
- the fungi are generally mutated in terms of their general characteristics, and are not uniform. Or it is a well-known fact to mutate by artificial mutation means using mutant derivatives, such as N-methyl-N'-nitro-1N-ditroguanidine, ethylmethanesulfonate, etc.
- Rhodococcus It belongs to the genus Rhodococcus, including naturally occurring mutants as well as mutants, and produces the K 0 1— B 0 1 7 1 substance represented by the above formulas [I] and [II] or a composition of the substance Any strain having capacity can be used in the present invention.
- the production of the substance K 0 1 -B 0 1 71 according to the present invention is carried out by first culturing a K 0 1 -B 0 1 71 substance producing bacterium belonging to the genus Orococcus in a medium.
- Nutrient sources suitable for the production of K 0 1 -B 0 1 7 1 substances of the present invention include carbon sources that can be assimilated by microorganisms, nitrogen sources that can be digested, and inorganic salts, vitamins, and the like as necessary.
- a nutrient medium is used.
- As the carbon source glucose, fructose, maltose, lactose, galactose, dextrin, saccharides such as starch, and vegetable oils such as soybean oil are used alone or in combination.
- peptone, yeast extract, meat extract, soybean flour, cottonseed flour, corn steep liquor, malt extract, casein, amino acids, urea, ammonium salts, nitrates, etc. are used alone or in combination.
- Others As required Phosphate, magnesium salt, calcium salt, sodium salt, potassium salt, etc.
- Heavy iron salt such as iron salt, manganese salt, copper salt, cobalt salt, zinc salt, vitamins, etc. K 0 1-B 0 1 7 1 Those suitable for the production of substances are added.
- the medium may be liquid or solid as long as it contains the above-mentioned nutrient sources. Usually, it is better to use a liquid medium for culture. In the case of small-scale production, culture using a flask is preferable. .
- the composition of the medium to be used and the medium to be used for production culture may be the same, or may be changed if necessary.
- the culture temperature can be appropriately changed within the range in which the present K 0 1—B 0 1 7 1 substance-producing bacterium produces the present K 0 1 -B 0 1 7 1 substance, but is usually 6 to 37, preferably 1 Incubate at around 7 ° C.
- the culture pH is usually 7 to 8, preferably about 7.
- the culture time varies depending on the culture conditions, but is usually about 4 days.
- the K 0 1 -B 0 1 71 substances accumulated in the culture thus obtained are usually present in the cultured cells.
- the means used to collect metabolites from normal microorganism cultures can be used alone or in any order, or Used repeatedly.
- this K 0 1—B 0 1 7 1 substance it may be collected from the bacterial cell extract.
- the cells are extracted with organic solvents such as acetone, ethanol or methanol.
- the substance K 0 1 — B 0 17 1 can be isolated by silica gel column chromatography, Sephadex LH-20, ODS column chromatography or the like.
- Solubility in solvents Soluble in water, dimethyl sulfoxide (DMSO), methanol, and ethanol. , Insoluble in acetononitrile, ethyl acetate, black mouth form, and aceton.
- Red external absorption spectrum Infrared absorption spectrum measured by the bromide-powered Rum tablet method is shown in Fig. 6 and shows a special absorption maximum at Ama X 1 650 cnr 1 .
- Solubility in solvents Soluble in water, dimethylsulfoxide (DMSO), methanol, and ethanol. Insoluble in acetononitrile, ethyl acetate, black mouth form, and aceton.
- the K01-BO 1 71—C substance has the chemistry represented by the following formula [II]. It was determined to be a structure.
- Myc ob acteri um sme gma tis as a tuberculosis bacterium (; storage stock of Kitasato Life Research Institute, Kasato University). Waxman agar medium NaC l 0.5% G lueose 1.0%, Agar r 0.8%) was inoculated at 0.3%. The activity was evaluated by the paper-disc method (thick 6 mm, manufactured by ADVANTECH, Japan), and the inhibition circle was measured after incubation at 27 ° C for 24 hours.
- the K0 1 -B 0171 1 B substance of the present invention exhibited a 19 mm inhibition circle at 10 ug / disk.
- the K 0 1 -B 0 1 71 1 C substance of the present invention exhibited an inhibition circle of 18 mm at 10 g / disk.
- This seed culture is equivalent to a mixture of McFar 1 and No. 0.5 (1% B a C 1 2 solution 0.05 mL, 1% H 2 S0 4 solution 9.95 mL at OD 630 nm. And 10 times diluted (10 times diluted culture solution: 10 7 C FU / mL). Wa k sma n br oth 90 ⁇ LZw e 1 1 dispensed 9 6-well microplate pre-prepared drug dilution series (3.9, 7.8, 1 5. 6, 31.
- the substance K 01 -B 0171-1 B of the present invention was M IC 3.13 ng / mL
- the substance K 01 -B 0171 1 C of the present invention was MI C 6.25 g / mL.
- Jurkat cells cultured in RPM I medium are centrifuged at 1000 rpm for 10 minutes, the supernatant is removed overnight, and RPMI medium is added to make the number of cells 5 x 10 5 cells sZm 1.
- RPMI medium is added to make the number of cells 5 x 10 5 cells sZm 1.
- the K0 1 -B 0 711 substance of the present invention has a new skeleton and is expected to be useful as a new antituberculosis drug effective against Mycobacterium tuberculosis.
- FIG. 1 shows the ultraviolet absorption spectrum (50% methanol in water) of the K 0 1 -B 0 71-B substance of the present invention.
- FIG. 2 shows the infrared absorption spectrum (potassium bromide tablet method) of substance K01-B 01 71-1 B of the present invention.
- FIG. 3 shows the proton nuclear magnetic resonance spectrum (heavy water) of the K 0 1 -B 0 1 71 -B substance of the present invention.
- FIG. 4 shows the carbon nuclear magnetic resonance spectrum (heavy water) of the K 01 -B 017 1-B substance of the present invention.
- FIG. 5 shows the ultraviolet absorption spectrum (50% methanol in water) of the K01-B 0 71-C substance of the present invention.
- FIG. 6 shows the infrared absorption spectrum (potassium bromide tablet method) of the substance K0 1 -B 0 1 71 1 C of the present invention.
- FIG. 7 shows the proton nuclear magnetic resonance spectrum [in heavy water-deuterated methanol (3: 2)] of the K01-B 0 71-C substance of the present invention.
- FIG. 8 shows the force-bonn nuclear magnetic resonance spectrum [in light water single methanol (3: 1)] of the K01-B 0 71 1-C material of the present invention.
- K 0 1—B 0 1 7 1—B substance and K 0 1 -B 0 1 7 1C substance or K belonging to the genus Rhodococcus having the ability to produce the composition of these substances Microorganisms typified by 0 1 -B 0 1 7 1 strain are cultured in a culture medium, and K 0 1—B 0 1 7 1—B substance and K0 1 -B 0 1 7 1—C substance are contained in the culture medium.
- the obtained substance or composition is expected to be an effective pharmaceutical agent for the prevention and treatment of tuberculosis because it has antituberculous activity.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2003/000349 WO2004065413A1 (ja) | 2003-01-17 | 2003-01-17 | 新規k01−b0171物質およびその製造法 |
JP2004567103A JP4185497B2 (ja) | 2003-01-17 | 2003-01-17 | 新規k01−b0171物質およびその製造法 |
US10/508,413 US7439225B2 (en) | 2003-01-17 | 2003-01-17 | Substances K01-B0171 and process for producing the same |
AU2003203250A AU2003203250B2 (en) | 2003-01-17 | 2003-01-17 | Novel substances K01-B0171 and process for producing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2003/000349 WO2004065413A1 (ja) | 2003-01-17 | 2003-01-17 | 新規k01−b0171物質およびその製造法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004065413A1 true WO2004065413A1 (ja) | 2004-08-05 |
Family
ID=32750552
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/000349 WO2004065413A1 (ja) | 2003-01-17 | 2003-01-17 | 新規k01−b0171物質およびその製造法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US7439225B2 (ja) |
JP (1) | JP4185497B2 (ja) |
AU (1) | AU2003203250B2 (ja) |
WO (1) | WO2004065413A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010202571A (ja) * | 2009-03-03 | 2010-09-16 | Kitasato Institute | 新規fki−4905物質およびその製造方法 |
JP2012503975A (ja) * | 2009-04-01 | 2012-02-16 | 湖南省天騎医学新技▲術▼有限公司 | 薬剤感受性試験方法および薬剤感受性試験装置 |
JP2013526874A (ja) * | 2010-06-02 | 2013-06-27 | 湖南省天騎医学新技▲術▼有限公司 | 結核菌の薬剤感受性試験法、インディケータの利用法、並びに固体培地 |
CN108485976A (zh) * | 2018-03-16 | 2018-09-04 | 华中科技大学 | 一种重金属抗性微生物的筛选方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4374764A (en) * | 1979-11-01 | 1983-02-22 | Sankyo Company, Limited | Macrolide antibiotic |
-
2003
- 2003-01-17 AU AU2003203250A patent/AU2003203250B2/en not_active Ceased
- 2003-01-17 WO PCT/JP2003/000349 patent/WO2004065413A1/ja active Application Filing
- 2003-01-17 JP JP2004567103A patent/JP4185497B2/ja not_active Expired - Fee Related
- 2003-01-17 US US10/508,413 patent/US7439225B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4374764A (en) * | 1979-11-01 | 1983-02-22 | Sankyo Company, Limited | Macrolide antibiotic |
Non-Patent Citations (2)
Title |
---|
HART D.H. ET AL.: "Lung infection casued by rhodococcus", AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, vol. 18, no. 6, October 1988 (1988-10-01), pages 790 - 791, XP002967685 * |
MIYAKAWA Y. ET AL.: "In vitro activity of the antimicrobial peptides human and rabbit defensins and porcine leukocyte protegrin against mycobacterium tuberculosis", INFECTION AND IMMUNITY, vol. 64, no. 3, 1996, pages 926 - 932, XP002920633 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010202571A (ja) * | 2009-03-03 | 2010-09-16 | Kitasato Institute | 新規fki−4905物質およびその製造方法 |
JP2012503975A (ja) * | 2009-04-01 | 2012-02-16 | 湖南省天騎医学新技▲術▼有限公司 | 薬剤感受性試験方法および薬剤感受性試験装置 |
JP2013526874A (ja) * | 2010-06-02 | 2013-06-27 | 湖南省天騎医学新技▲術▼有限公司 | 結核菌の薬剤感受性試験法、インディケータの利用法、並びに固体培地 |
CN108485976A (zh) * | 2018-03-16 | 2018-09-04 | 华中科技大学 | 一种重金属抗性微生物的筛选方法 |
Also Published As
Publication number | Publication date |
---|---|
US20060089298A1 (en) | 2006-04-27 |
JPWO2004065413A1 (ja) | 2006-05-18 |
AU2003203250B2 (en) | 2006-05-11 |
AU2003203250A1 (en) | 2004-08-13 |
JP4185497B2 (ja) | 2008-11-26 |
US7439225B2 (en) | 2008-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3140228B2 (ja) | 新規な大環状ラクトンおよびその生産菌 | |
JPS58180487A (ja) | 抗生物質dc−81およびその製造法 | |
JP4439401B2 (ja) | マクロライド系化合物の製造方法 | |
JP4521145B2 (ja) | 抗生物質カプラザマイシン類およびその製造法 | |
KR101566046B1 (ko) | 환형 화합물을 생산하는 미생물 | |
CN108794368B (zh) | 一种具有多样抑菌活性的生物碱类化合物及其制备方法及应用 | |
JP4104741B2 (ja) | ビタミンk高生産性菌株及びそれを用いたビタミンkの生産方法 | |
WO2004065413A1 (ja) | 新規k01−b0171物質およびその製造法 | |
WO1998056755A1 (fr) | Substances physiologiquement actives tkr2449, leur procede de preparation et micro-organisme | |
CN111172049A (zh) | 一株毒黄素高产菌株及其应用 | |
JPS5867189A (ja) | テトラエン抗真菌性抗生物質およびその製造方法 | |
JP5144167B2 (ja) | 新規kb−3346−5物質およびその製造方法 | |
WO2010122669A1 (ja) | 新規化合物アミコラマイシン、その製造方法及びその用途 | |
JP3902530B2 (ja) | 新規抗生物質キガマイシン類とその用途 | |
WO1997001575A1 (fr) | Substance wf16616, procede de production et utilisation | |
CN113215064B (zh) | 一株产美沙达唑类化合物的黏细菌及其应用 | |
JP4342048B2 (ja) | 抗生物質ツベラクトマイシンb、dおよびeとその製造法 | |
JP4759756B2 (ja) | 抗生物質カプラザマイシンd、g、d1、g1とその製造法 | |
WO2005111055A1 (ja) | 新規抗生物質キガマイシン類とその用途 | |
JP4755248B2 (ja) | 新規な抗生物質、ビスポライドA1、A2およびA3ならびにビスポライドB1、B2a、B2bおよびB3と、それら抗生物質の製造方法 | |
JP2005261309A (ja) | プロジギオシン類色素の製造方法およびそれに使用する新規な微生物 | |
JP2005218320A (ja) | 新規抗真菌物質fa424a(n)、fa424a(o)、fa424b、及びfa424d | |
JPS59151896A (ja) | 新規抗生物質ss8201b及びその製造法 | |
JPH0984591A (ja) | カロテノイド硫酸エステルおよびその製造方法 | |
JPH01308293A (ja) | 抗菌および抗腫瘍剤LL―E33288ε―IおよびLL―E33288ε―Br、前記剤を生産する方法および中間体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003203250 Country of ref document: AU |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004567103 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2006089298 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10508413 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase | ||
WWP | Wipo information: published in national office |
Ref document number: 10508413 Country of ref document: US |